Discovering
Tomorrow’s
Treatments Today
The Ivy Brain Tumor Center is a nonprofit translational research program that offers state-of-the-art clinical trials for patients with even the most aggressive brain tumors.
Brain Tumor Treatment at Ivy
The Ivy Brain Tumor Center is a leader in brain tumor research and treatment. The Ivy Center is located in Phoenix, Arizona, at Barrow Neurological Institute, the highest-volume operative brain tumor center in the U.S.
Whether benign or malignant, a brain tumor can be life-changing. The Ivy Center’s multidisciplinary team of healthcare professionals and scientists work to understand the molecular structure of each patient’s brain tumor to determine its pathology and the most effective treatment plan. Explore a variety of brain tumor types we treat.
Tumors we treat
As one of the world’s largest brain tumor treatment centers, the Ivy Center utilizes advanced therapies, state-of-the-art technology and innovative clinical trials to tailor each patient’s treatment plan to their individualized needs and circumstances. No two brain tumors are alike and each tumor requires a treatment regimen designed for its unique genetic composition.
While each patient’s brain tumor experience is different, those on the receiving end of the diagnosis share the overwhelming feelings of worry, fear and stress. No one should have to cope with a brain cancer diagnosis alone. We understand the uncertainty of your circumstances. Our team is here for you every step of the way.
Clinical Trials
Ivy Brain Tumor Center clinical trials play a pivotal role in developing new therapies and advancing treatment options that make a significant impact on patient outcomes. The Ivy Center operates the world’s largest Phase 0 clinical trials program in the world.
What are Phase 0 Clinical Trials?
Clinical trials test new drugs, equipment and treatments that have not yet been approved. Phase 0 clinical trials study whether new drugs reach the intended brain tumor target and have the desired effect. This allows us to quickly advance drugs that show promise while eliminating those that do not.
What to Expect
Based on a combination of clinical, demographic and tumor genetics criteria, eligible patients are welcomed to an in-person consultation with an Ivy Center Navigator, who will guide them through the clinical trial process.
Explore Current Trials
Our brain tumor clinical trials are designed with the goal of discovering a breakthrough in brain cancer treatment. Explore active clinical trials currently enrolling at the Ivy Brain Tumor Center.
Complete Trial Screening Today
Each Ivy clinical trial has unique enrollment criteria. If you want to learn whether you or a loved one may be eligible, please submit a free trial screening request here or call 602-406-8605 to speak to an Ivy Navigator.
Latest from Ivy
News
Ivy Brain Tumor Center Announces Completion of Enrollment in Phase 3 Gliofocus Study for Patients with Newly-Diagnosed Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute today announced completion of randomization in the landmark Phase 3 Gliofocus study, a global trial evaluating niraparib versus standard-of-care temozolomide in adults with newly diagnosed, MGMT-unmethylated glioblastoma (GBM).
News
Advancing Brain Tumor Research: A New Phase 0/1 clinical trial at the Ivy Brain Tumor Center
The Ivy Brain Tumor Center announces the activation of a new clinical trial evaluating a B7-H3-targeted antibody-drug conjugate (ADC), risvutatug rezetecan (Ris-Rez), in recurrent grade 4 glioma and brain metastases. Ris-Rez is designed to deliver a therapeutic payload to tumor cells that express B7-H3.
News
2026 Barrow Grand Ball Ball Raises $5.1 Million for Brain Cancer Research
An impressive $5.1 million was raised specifically through the Ball to help advance critical research at the Ivy Center.
News
An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma
Last week, the Ivy Brain Tumor Center published a manuscript in Science Translational Medicine authored by Nader Sanai, MD, Shwetal Mehta, PHD, Artak Tovmasyan, PHD, An-Chi Tien, PHD, Igor Barani, MD, Charuta Furey, MD, and Zaman Mirzadeh, MD, in collaboration with other Ivy Center team members. The manuscript presents results from our early phase clinical trial utilizing sonodynamic therapy (SDT) in recurrent high-grade glioma patients. SDT pairs 5-aminolevulinic acid (5-ALA), which is metabolized to protoporphyrin IX in glioma cells, with noninvasive, image-guided focused ultrasound to trigger tumor-selective oxidative injury.
News
Phase 3 Gliofocus Study Drug, Niraparib, Granted Orphan Drug Designation by U.S. FDA for Treatment of Malignant Glioma, including Glioblastoma
The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported…
Videos
Tomorrow's Treatments Today, Tailored to Every Exception
